AZD 9773

Drug Profile

AZD 9773

Alternative Names: AZD9773; CytoFab

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protherics
  • Developer AstraZeneca; BTG; Protherics
  • Class Polyclonal antibodies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Coronary disorders; Crohn's disease; Graft-versus-host disease; Jarisch-Herxheimer reaction; Malaria; Septic shock; Transplant rejection

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Aug 2012 Discontinued - Phase-II for Septic shock in Australia (IV)
  • 08 Aug 2012 Discontinued - Phase-II for Septic shock in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top